Pharma bets a little-known type of cholesterol will underpin its next blockbuster heart drugs

Novartis, Amgen and Eli Lilly are targeting severe LDL reduction as a potential new blockbuster opportunity in cardiology. The article is largely forward-looking and frames the drugs as a competitive bet rather than reporting a concrete clinical or financial result. Market impact is limited unless later data show clear efficacy or commercial traction.

Analysis

Novartis, Amgen and Eli Lilly are targeting severe LDL reduction as a potential new blockbuster opportunity in cardiology. The article is largely forward-looking and frames the drugs as a competitive bet rather than reporting a concrete clinical or financial result. Market impact is limited unless later data show clear efficacy or commercial traction.